A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Jaison Grimes, MD
Primary Investigator
Brief description of study
We are working to understand if an investigational drug could be sage and potentially effective in promoting the repair of damaged tissue in the brain and spinal cord caused by MS, possibly impacting motor function.
Detailed description of study
If you qualify and decide to take part, your total time would be about 17 visits over about 19 months. What happens each visit will vary, but may include blood and urine samples, MRI scans and questionnaires.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Multiple Sclerosis
-
Age: 18 years - 55 years
-
Gender: All
Inclusion Criteria
Have primary-progressive MS, secondary-progressive MS or relapsing-remitting MS
Are on a stable dose of MS medication for at least 6 months or have been in stable condition without and an MS immunotherapy or corticosteroid for at least 6 months
